Uterine Corpus Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: UTR033 MIFTS: 44	Uterine Corpus Cancer Categories: Cancer diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Uterine Corpus Cancer

MalaCards integrated aliases for Uterine Corpus Cancer:

Name: Uterine Corpus Cancer ¹¹ ¹⁴ ¹⁶ ⁷¹

Malignant Uterine Corpus Neoplasm ⁷¹

Corpus Uteri Cancer ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

Malignant neoplasms of female genital organs

Malignant neoplasm of corpus uteri

Malignant neoplasm: Corpus uteri, unspecified

External Ids:

Disease Ontology ¹¹ DOID:9460

ICD9CM ³⁴ 182

NCIt ⁴⁹ C3556

SNOMED-CT ⁶⁸ 93718007

ICD10 ³¹ C54 C54.9

EFO ¹⁶ EFO_0007532

UMLS ⁷¹ C0153574 C1883486

Sources

Summaries for Uterine Corpus Cancer

Disease Ontology: ¹¹ A uterine cancer that is located in the uterine corpus.

MalaCards based summary: Uterine Corpus Cancer, also known as malignant uterine corpus neoplasm, is related to endometrial cancer and uterine corpus endometrial carcinoma. An important gene associated with Uterine Corpus Cancer is H2AC18 (H2A Clustered Histone 18), and among its related pathways/superpathways are Endometrial cancer and Development EGFR signaling pathway. The drugs Doxorubicin and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include uterine corpus, breast and ovary, and related phenotypes are Increased shRNA abundance (Z-score > 2) and neoplasm

Sources

Related Diseases for Uterine Corpus Cancer

Diseases related to Uterine Corpus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 326)

#	Related Disease	Score	Top Affiliating Genes
1	endometrial cancer	32.3	TP53 PTEN PIK3CA MIR200C HRAS H2AC18
2	uterine corpus endometrial carcinoma	32.3	TP53 PTEN PPP2R1A PIK3CA ARID1A
3	uterine body mixed cancer	32.0	U2AF1 TP53 SLC25A16 PTEN PPP2R1A POLE
4	endometrial serous adenocarcinoma	31.9	TP53 PTEN PPP2R1A POLE PIK3CA MIR34C
5	adenocarcinoma	30.7	TP53 PTEN PIK3CA HRAS ERBB2
6	endometriosis	30.7	TP53 PTEN MIR34C MIR200C
7	papillary serous adenocarcinoma	30.6	TP53 HRAS ERBB2
8	bladder cancer	30.5	TP53 PTEN PIK3CA MIR10B HRAS H2AC18
9	cervical cancer	30.4	U2AF1 TP53 PTEN PIK3CA MIR101-1 HRAS
10	serous cystadenocarcinoma	30.3	TP53 PTEN PPP2R1A POLE PIK3CA HRAS
11	ovarian cancer	30.1	TP53 PTEN PPP2R1A PIK3CA MIR34C MIR34B
12	uterine corpus sarcoma	11.2
13	mixed endometrial stromal and smooth muscle tumor	11.2
14	cystadenocarcinoma	10.5	TP53 PTEN ARID1A
15	high-grade astrocytoma	10.5	TP53 PTEN
16	esophagus small cell carcinoma	10.5	PIK3CA ERBB2
17	anal squamous cell carcinoma	10.5	TP53 PIK3CA H2AC18
18	familial ovarian cancer	10.5	TP53 POLE
19	wolffian duct adenocarcinoma	10.5	U2AF1 PIK3CA
20	apocrine adenocarcinoma	10.5	TP53 PIK3CA ERBB2
21	lung oat cell carcinoma	10.5	TP53 PTEN PIK3CA
22	vaginal carcinosarcoma	10.5	TP53 PIK3CA HRAS
23	intraductal breast benign neoplasm	10.5	TP53 PIK3CA ERBB2
24	breast benign neoplasm	10.5	TP53 PIK3CA ERBB2
25	peritoneum cancer	10.5	TP53 H2AC18 ERBB2
26	apocrine adenosis of breast	10.5	TP53 ERBB2
27	t-cell prolymphocytic leukemia	10.5	TP53 MIR200C H2AC18
28	esophagus verrucous carcinoma	10.5	TP53 PIK3CA
29	diffuse astrocytoma	10.5	TP53 PTEN H2AC18
30	mixed glioma	10.5	TP53 SIGLEC5 PTEN
31	acute erythroid leukemia	10.5	U2AF1 TP53 H2AC18
32	synchronous bilateral breast carcinoma	10.5	TP53 PTEN ERBB2
33	splenic disease	10.5	U2AF1 SIGLEC5 H2AC18
34	keratinizing squamous cell carcinoma	10.5	TP53 PIK3CA HRAS
35	adenocarcinoma in situ	10.5	U2AF1 TP53 HRAS
36	papillary adenofibroma	10.5	PTEN POLE ARID1A
37	thoracic benign neoplasm	10.5	TP53 PIK3CA ERBB2
38	blood protein disease	10.5	U2AF1 TP53 H2AC18
39	childhood medulloblastoma	10.5	TP53 H2AC18 ERBB2
40	vulva squamous cell carcinoma	10.5	TP53 PIK3CA HRAS
41	fallopian tube disease	10.5	TP53 SIGLEC5 H2AC18 ERBB2
42	ovarian clear cell adenocarcinoma	10.5	TP53 PIK3CA H2AC18 ARID1A
43	gallbladder adenocarcinoma	10.5	TP53 HRAS ERBB2
44	adrenal cortex disease	10.5	TP53 MIR139 MIR101-1 H2AC18
45	lung large cell carcinoma	10.5	TP53 HRAS H2AC18
46	glioma	10.5	TP53 PTEN PIK3CA MIR10B
47	thyroid tumor	10.5	PTEN PIK3CA HRAS
48	vaginal cancer	10.5	TP53 PTEN HRAS
49	clear cell adenofibroma	10.5	PIK3CA ARID1A
50	mucosal melanoma	10.4	U2AF1 PTEN HRAS

Graphical network of the top 20 diseases related to Uterine Corpus Cancer:

Sources

Symptoms & Phenotypes for Uterine Corpus Cancer

GenomeRNAi Phenotypes related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

²⁵ (show all 29)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-1	10.15	POLE
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-123	10.15	POLE
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	10.15	PTEN
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-16	10.15	PTEN
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-161	10.15	ERBB2
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-168	10.15	ERBB2 POLE PTEN ARID1A
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-176	10.15	ARID1A
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-186	10.15	ARID1A
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-190	10.15	ARID1A
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-196	10.15	HRAS
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-199	10.15	POLE
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-207	10.15	ERBB2 POLE
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-213	10.15	ARID1A
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	10.15	PTEN
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-28	10.15	HRAS
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-32	10.15	ERBB2 POLE
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-42	10.15	PTEN
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	10.15	ARID1A
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-60	10.15	ERBB2
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	10.15	ERBB2 POLE PTEN
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-66	10.15	PTEN
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-73	10.15	ARID1A
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-82	10.15	H2AC18
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-83	10.15	HRAS
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	10.15	ERBB2 POLE
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-87	10.15	ERBB2 HRAS POLE PTEN
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-91	10.15	POLE
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-93	10.15	PTEN
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-99	10.15	H2AC18

MGI Mouse Phenotypes related to Uterine Corpus Cancer:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	9.32	ARID1A ERBB2 HRAS MIR139 PIK3CA POLE

Sources

Drugs & Therapeutics for Uterine Corpus Cancer

Drugs for Uterine Corpus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Doxorubicin

Approved, Investigational

Phase 3

23214-92-8

31703

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Pembrolizumab

Approved

Phase 3

1374853-91-4

254741536

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Metformin

Approved

Phase 2, Phase 3

1115-70-4, 657-24-9

4091

Immunologic Factors

Phase 3

Antibiotics, Antitubercular

Phase 3

Liposomal doxorubicin

Phase 3

Adjuvants, Immunologic

Phase 3

Antineoplastic Agents, Immunological

Phase 3

Albumin-Bound Paclitaxel

Phase 3

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Hypoglycemic Agents

Phase 2, Phase 3

Fulvestrant

Approved, Investigational

Phase 2

129453-61-8

17756771 104741

Sodium citrate

Approved, Investigational

Phase 2

68-04-2

23431961

Tamoxifen

Approved

Phase 2

10540-29-1, 54965-24-1

2733526

Medroxyprogesterone acetate

Approved, Investigational

Phase 2

520-85-4, 71-58-9

6279 10631

Bupropion

Approved

Phase 2

31677-93-7, 34841-39-9, 34911-55-2

444

Dopamine

Approved

Phase 2

62-31-7, 51-61-6

681

Trastuzumab

Approved, Investigational

Phase 2

180288-69-1

Everolimus

Approved

Phase 2

159351-69-6

70789204 6442177

Letrozole

Approved, Investigational

Phase 2

112809-51-5

3902

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

Palbociclib

Approved, Investigational

Phase 2

571190-30-2

5330286

Mebendazole

Approved, Vet_approved

Phase 2

31431-39-7

4030

Piperazine

Approved, Vet_approved

Phase 2

110-85-0

4837

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Racepinephrine

Approved, Vet_approved

Phase 2

51-43-4, 329-65-7

838 5816

Afatinib

Approved

Phase 2

439081-18-2, 850140-72-6

53445376 10184653

Adenosine

Approved, Investigational

Phase 2

58-61-7

60961

Trametinib

Approved

Phase 2

871700-17-3

11707110

Pertuzumab

Approved

Phase 2

380610-27-5

Dabrafenib

Approved, Investigational

Phase 2

1195765-45-7

44462760

Osimertinib

Approved

Phase 2

1421373-65-0

71496458

Crizotinib

Approved, Investigational

Phase 2

877399-52-5

11626560

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Dasatinib

Approved, Investigational

Phase 2

302962-49-8

3062316

Levonorgestrel

Approved, Investigational

Phase 2

797-63-7

13109

Olaparib

Approved

Phase 1, Phase 2

763113-22-0

23725625

Nivolumab

Approved

Phase 2

946414-94-4

Doxycycline

Approved, Investigational, Vet_approved

Phase 2

564-25-0

54671203

Megestrol acetate

Approved, Investigational, Vet_approved

Phase 2

595-33-5

11683

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 2

77-92-9

311

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 2

133585-56-5, 60-18-4, 556-02-5

1153 6057

Interventional clinical trials:

(show top 50) (show all 80)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma	Unknown status	NCT00807768	Phase 3	Carboplatin;Paclitaxel
2	Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients With Stage III &Amp; IV or Recurrent Endometrial Cancer	Completed	NCT00063999	Phase 3	Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
3	A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III	Completed	NCT00002706	Phase 3
4	A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma	Completed	NCT00006011	Phase 3	Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
5	A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer	Active, not recruiting	NCT02065687	Phase 2, Phase 3	Carboplatin;Metformin Hydrochloride;Paclitaxel
6	A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma	Active, not recruiting	NCT00942357	Phase 3	Carboplatin;Cisplatin;Paclitaxel
7	A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer	Active, not recruiting	NCT04214067	Phase 3
8	A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer	Active, not recruiting	NCT03914612	Phase 3	Carboplatin;Paclitaxel
9	Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE)	Active, not recruiting	NCT03422198	Phase 3
10	Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel	Active, not recruiting	NCT02501954	Phase 3	Cisplatin;Carboplatin;Paclitaxel
11	A Prospective Randomized Single Blind Phase III Trial Comparing Flexitouch Home Maintenance Therapy to Standard Home Maintenance Therapy for Lower Extremity Lymphedema Resulting From Treatment of Gynecologic Malignancy	Terminated	NCT00577317	Phase 3
12	Phase II Study of Faslodex ? in Recurrent/Metastatic Endometrial Carcinoma	Unknown status	NCT00006903	Phase 2	Fulvestrant
13	A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer	Completed	NCT01005329	Phase 2	Carboplatin;Cisplatin;Paclitaxel
14	A Randomized Phase II Trial of Temsirolimus (NCI-Supplied Agent, NSC # 683864) or the Combination of Hormonal Therapy Plus Temsirolimus in Women With Advanced, Persistent, or Recurrent Endometrial Carcinoma	Completed	NCT00729586	Phase 2	Megestrol Acetate;Tamoxifen Citrate;Temsirolimus
15	A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer	Completed	NCT01010126	Phase 2	Temsirolimus
16	A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus	Completed	NCT00064025	Phase 2	Medroxyprogesterone
17	A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma	Completed	NCT00478426	Phase 2	Sunitinib Malate
18	A Phase II Evaluation of Trastuzumab (MoAb HER2) in Patients With Advanced, Recurrent or Persistent Endometrial Carcinoma With or Without Prior Chemotherapy	Completed	NCT00006089	Phase 2
19	A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations	Completed	NCT02728258	Phase 2	Copanlisib
20	Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer	Completed	NCT03180294	Phase 2	Bupropion 150 mg XL;Placebo
21	A Phase II, Randomized Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (LEE011) in Patients With Advanced or Recurrent Endometrial Carcinoma	Recruiting	NCT03008408	Phase 2	Everolimus;Letrozole;Ribociclib
22	A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer	Recruiting	NCT03660826	Phase 2	Capivasertib;Cediranib;Cediranib Maleate;Olaparib
23	Molecular Analysis for Therapy Choice (MATCH)	Recruiting	NCT02465060	Phase 2	Adavosertib;Afatinib;Afatinib Dimaleate;Binimetinib;Capivasertib;Copanlisib;Copanlisib Hydrochloride;Crizotinib;Dabrafenib;Dabrafenib Mesylate;Dasatinib;Defactinib;Defactinib Hydrochloride;Erdafitinib;FGFR Inhibitor AZD4547;Ipatasertib;Larotrectinib;Larotrectinib Sulfate;Osimertinib;Palbociclib;PI3K-beta Inhibitor GSK2636771;Sapanisertib;Sunitinib Malate;Taselisib;Trametinib;Ulixertinib;Vismodegib
24	A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer	Active, not recruiting	NCT02684227	Phase 2	Carboplatin;Enzalutamide;Paclitaxel
25	A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer	Active, not recruiting	NCT00977574	Phase 2	Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
26	Step Into Wellness: A Program of Health and Recovery for Endometrial Cancer Survivors	Active, not recruiting	NCT03367923	Phase 2
27	A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer	Active, not recruiting	NCT01935934	Phase 2	Cabozantinib S-malate
28	A Phase II Study of the Levonorgestrel Intrauterine Device (Mirena) to Treat Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Carcinoma	Active, not recruiting	NCT00788671	Phase 2
29	A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer	Active, not recruiting	NCT03367741	Phase 2	Cabozantinib S-malate
30	A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Active, not recruiting	NCT02208375	Phase 1, Phase 2	Capivasertib;Olaparib;Vistusertib
31	A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma	Active, not recruiting	NCT03348631	Phase 2	Tazemetostat
32	A Phase II Trial of DCTD-Sponsored Dasatinib in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression	Active, not recruiting	NCT02059265	Phase 2	Dasatinib
33	A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus	Active, not recruiting	NCT00492778	Phase 2	Cisplatin
34	A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer	Active, not recruiting	NCT02874430	Phase 2	Metformin Hydrochloride;Doxycycline
35	A Phase IB and Randomized Phase II Trial of Megestrol Acetate With or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer	Not yet recruiting	NCT05538897	Phase 1, Phase 2	Ipatasertib;Megestrol Acetate
36	A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With High-Risk Endometrial Cancer After Standard Surgical Staging	Terminated	NCT01041027	Phase 2	Paclitaxel;Carboplatin
37	A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma	Terminated	NCT02112552	Phase 2	Paclitaxel;Carboplatin
38	A Randomized Phase II Evaluation of Continuous Progestin Therapy vs. Sequential Progestin Therapy in the Treatment of Endometrial Intraepithelial Neoplasia (EIN) From a Referred Cohort of Atypical Endometrial Hyperplasia (AEH) or EIN Patients That Desire Uterine Preservation	Terminated	NCT00503581	Phase 2	Megestrol Acetate
39	A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors	Completed	NCT01522820	Phase 1	Sirolimus
40	Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplatin in Women With Advanced Stage and Recurrent Endometrial Cancer	Completed	NCT01440998	Phase 1	Carboplatin;Dasatinib;Paclitaxel
41	A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure	Completed	NCT00575952	Phase 1	Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
42	A Phase I Study of Halichondrin B Analog E7389 in Combination With Gemcitabine in Patients With Refractory or Advanced Solid Tumors	Completed	NCT00410553	Phase 1	Eribulin Mesylate;Gemcitabine Hydrochloride
43	Phase I Trial of the Treatment of Advanced Endometrial Cancer With Concurrent Weekly Paclitaxel and Cisplatin and Whole Abdominal Radiation Therapy	Completed	NCT00005840	Phase 1	Paclitaxel;Cisplatin
44	Phase I Toxicity Trial of Doxorubicin-Cisplatin Followed by Whole Abdominal Irradiation for Advanced Endometrial Carcinoma	Completed	NCT00005830	Phase 1	Doxorubicin Hydrochloride;Cisplatin
45	A Randomized Phase I Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer NCT #01935973	Completed	NCT01935973	Phase 1	Trametinib;Uprosertib
46	Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)	Recruiting	NCT04704661	Phase 1	Ceralasertib
47	A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)	Recruiting	NCT05269381	Phase 1	Cyclophosphamide
48	Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib, or With Atezolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax	Recruiting	NCT05092373	Phase 1	Cabozantinib S-malate;Nab-paclitaxel
49	A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors	Recruiting	NCT05039801	Phase 1	Glutaminase Inhibitor IPN60090;Bevacizumab;Paclitaxel
50	Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC)	Recruiting	NCT04329494	Phase 1	Cisplatin;Doxorubicin;Fluorouracil;Irinotecan;Leucovorin;Mitomycin;Oxaliplatin

Search NIH Clinical Center for Uterine Corpus Cancer

Sources

Genetic Tests for Uterine Corpus Cancer

Sources

Anatomical Context for Uterine Corpus Cancer

Organs/tissues related to Uterine Corpus Cancer:

FMA: Uterine Corpus

MalaCards : Breast, Ovary, Cervix, Prostate, Endothelial, Liver, Lymph Node

Sources

Publications for Uterine Corpus Cancer

Articles related to Uterine Corpus Cancer:

(show top 50) (show all 262)

#	Title	Authors	PMID	Year
1	Enhanced Recovery after Uterine Corpus Cancer Surgery: A 10 Year Retrospective Cohort Study of Robotic Surgery in an NHS Cancer Centre. ⁶²	Uwins C...Butler-Manuel S	36358881	2022
2	Temporal trends and factors associated with the cancer diagnosed at stage IV in patients included in the integrated hospital-based cancer registry system in Brazil in two decades. ⁶²	Oliveira LC...Thuler LCS	36087358	2022
3	Development of healthy lifestyle consciousness index for gynecological cancer patients. ⁶²	Higashiyama N...Mandai M	35674795	2022
4	COX2 Effects on endometrial carcinomas progression. ⁶²	Lyndin M...Romaniuk A	36049440	2022
5	Long-term risk of uterine malignancies in women with uterine fibroids confirmed by myomectomy: a population-based study. ⁶²	Yuk JS...Kim M	35775461	2022
6	Cancer incidence and mortality in Poland in 2019. ⁶²	Didkowska J...Caetano Dos Santos FL	35760845	2022
7	Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype. ⁶²	Clarke MA...Wentzensen N	35511145	2022
8	Completeness and selection bias of a Belgian multidisciplinary, registration-based study on the EFFectiveness and quality of Endometrial Cancer Treatment (EFFECT). ⁶²	Vanbraband J...Amant F	35650593	2022
9	Disseminated Primary Uterine Hepatoid Adenocarcinoma with α-Fetoprotein Production Demonstrated on 18F-FDG PET/CT. ⁶²	Dejanovic D...Noettrup TJ	35741257	2022
10	Major clinical research advances in gynecologic cancer in 2021. ⁶²	Park JY...Kim JW	35245004	2022
11	Associations of genetic susceptibility to 16 cancers with risk of breast cancer overall and by intrinsic subtypes. ⁶²	Choi J...Zheng W	35047862	2022
12	Trends in Incidence and Mortality of Gynecological and Breast Cancers in Poland (1980-2018). ⁶²	Piechocki M...Banas T	35115839	2022
13	Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: Results from the first Italian population-based cohort. ⁶²	Trama A...Bernasconi A	34582036	2022
14	Improved long-term survival of corpus cancer in Japan: A 40-year population-based analysis. ⁶²	Yagi A...Kimura T	34494658	2022
15	Risk and prognosis of second corpus uteri cancer after radiation therapy for pelvic cancer: A population-based analysis. ⁶²	Yu G...Jiang Z	36249002	2022
16	Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status. ⁶²	Sung H...Jemal A	34002851	2021
17	Body composition and risk of major gynecologic malignancies: Results from the UK Biobank prospective cohort. ⁶²	Yun P...Li FP	34114748	2021
18	Major clinical research advances in gynecologic cancer in 2020. ⁶²	Lee YY...Kim JW	34085794	2021
19	Association of laboratorial parameters and prognostic factors in uterine corpus cancer. ⁶²	Bezerra KRV...Nomelini RS	34550258	2021
20	Trends in hysterectomy-corrected uterine cancer mortality rates during 2002 to 2015: mortality of nonendometrioid cancer on the rise? ⁶²	Gustafson LW...Hammer A	32683690	2021
21	A national surveillance study of the current status of reirradiation using brachytherapy in Japan. ⁶²	Yamazaki H...JBReRT Group	32888854	2021
22	Body mass index and waist circumference in relation to the risk of 26 types of cancer: a prospective cohort study of 3.5 million adults in Spain. ⁶²	Recalde M...Duarte-Salles T	33441148	2021
23	[Incidence and mortality of corpus uteri cancer in China, 2015]. ⁶²	Ma JY...He J	33472322	2021
24	Age-specific corpus uteri cancer incidence rate in the world. ⁶²	Niino M...Matsuda T	33089865	2020
25	Years of life lost due to premature death and their trends in people with malignant neoplasm of female genital organs in Shanghai, China during 1995-2018: a population based study. ⁶²	Luo Z...Du Y	33004024	2020
26	Clinical and histopathologic analysis of gynecological cancer: a single institute experience over 7 years. ⁶²	Lee SY...Lee DH	32131080	2020
27	Trends in Mortality Rates of Corpus Uteri and Ovarian Cancer in Lithuania, 1987-2016. ⁶²	Everatt R...Intaite B	32668695	2020
28	National and Subnational Trends of Incidence and Mortality of Female Genital Cancers in Iran; 1990-2016. ⁶²	Eftekharzadeh S...Farzadfar F	32657594	2020
29	Major clinical research advances in gynecologic cancer in 2019. ⁶²	Kim M...Kim JW	32319232	2020
30	Hyaluronic acid gel injection in rectovaginal septum reduced incidence of rectal bleeding in brachytherapy for gynecological malignancies. ⁶²	Murakami N...Itami J	31879238	2020
31	Investigating the Nexus between Gynaecologic Cancer and Human Development Index. ⁶²	Pervaiz R...Faisal F	32358937	2020
32	Association between the incidence and mortality rates for corpus uteri cancer and human development index (HDI): a global ecological study. ⁶²	Khazaei Z...Mansori K	32206653	2020
33	Impact of maternal reproductive factors on cancer risks of offspring: A systematic review and meta-analysis of cohort studies. ⁶²	Han MA...Guyatt G	32226046	2020
34	Mortality prediction in women with corpus uteri cancer in Brazil: a 21-year analysis. ⁶²	Dantas DB...de Melo-Neto JS	32419841	2020
35	Increasing incidence and survival of corpus uteri cancer in Estonia over the past two decades. ⁶²	Ojamaa K...Innos K	31326850	2019
36	Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial. ⁶²	Tamura K...Minami H	31348579	2019
37	Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers. ⁶²	Clarke MA...Wentzensen N	31116674	2019
38	Beyond Obesity: The Rising Incidence and Mortality Rates of Uterine Corpus Cancer. ⁶²	Mullins MA...Cote ML	31232669	2019
39	Vitamin D levels and cancer incidence in 217,244 individuals from primary health care in Denmark. ⁶²	Vojdeman FJ...Schwarz P	30613979	2019
40	Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy. ⁶²	Desai VB...Xu X	30853364	2019
41	Incidence and mortality of corpus uteri cancer in China, 2008-2012. ⁶²	Xi Y...Chen W	31354212	2019
42	Overweight in midlife and risk of cancer in late life: A nationwide Swedish twin study. ⁶²	Bao C...Xu W	30565668	2019
43	A proposal for updating the staging of endometrial cancer. ⁶²	Maheshwari A...Prat J	30776091	2019
44	Mistletoe in oncological treatment: a systematic review : Part 2: quality of life and toxicity of cancer treatment. ⁶²	Freuding M...Huebner J	30673872	2019
45	Mistletoe in oncological treatment: a systematic review : Part 1: survival and safety. ⁶²	Freuding M...Huebner J	30673873	2019
46	Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. ⁶²	Sung H...Jemal A	30733056	2019
47	The EMPCAN study: protocol of a population-based cohort study on the evolution of the socio-economic position of workers with cancer. ⁶²	Kiasuwa-Mbengi RL...Bouland C	30937166	2019
48	Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000-2014. ⁶²	Teepen JC...Morton LM	29795414	2018
49	Secondary Breast, Ovarian, and Uterine Cancers After Colorectal Cancer: A Nationwide Population-Based Cohort Study in Korea. ⁶²	Shin DW...Lee DH	30239394	2018
50	Advancing Uterine Cancer Survivorship Among African American Women. ⁶²	Coughlin SS...Anglin J	30126566	2018

Sources

Genes for Uterine Corpus Cancer

Genes related to Uterine Corpus Cancer (0 elite genes):

(show top 50) (show all 54)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	H2AC18	H2A Clustered Histone 18	Protein Coding	7.7	DISEASES inferred ¹⁴ ¹⁴
2	DLEU1	Deleted In Lymphocytic Leukemia 1	RNA Gene	7.69	DISEASES inferred ¹⁴ ¹⁴
3	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	7.64	DISEASES inferred ¹⁴ ¹⁴
4	MIR200C	MicroRNA 200c	RNA Gene	7.46	DISEASES inferred ¹⁴ ¹⁴
5	MIR139	MicroRNA 139	RNA Gene	7.24	DISEASES inferred ¹⁴ ¹⁴
6	TP53	Tumor Protein P53	Protein Coding	7.16	DISEASES inferred ¹⁴
7	POLE	DNA Polymerase Epsilon, Catalytic Subunit	Protein Coding	7.07	DISEASES inferred ¹⁴
8	SIGLEC5	Sialic Acid Binding Ig Like Lectin 5	Protein Coding	7.06	DISEASES inferred ¹⁴ ¹⁴
9	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	6.9	DISEASES inferred ¹⁴
10	MIR101-1	MicroRNA 101-1	RNA Gene	6.89	DISEASES inferred ¹⁴ ¹⁴
11	PPP2R1A	Protein Phosphatase 2 Scaffold Subunit Aalpha	Protein Coding	6.85	DISEASES inferred ¹⁴
12	SLC25A16	Solute Carrier Family 25 Member 16	Protein Coding	6.85	DISEASES inferred ¹⁴
13	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	6.74	DISEASES inferred ¹⁴
14	PTEN	Phosphatase And Tensin Homolog	Protein Coding	6.71	DISEASES inferred ¹⁴
15	ARID1A	AT-Rich Interaction Domain 1A	Protein Coding	6.65	DISEASES inferred ¹⁴
16	MIR10B	MicroRNA 10b	RNA Gene	6.56	DISEASES inferred ¹⁴ ¹⁴
17	MIR34B	MicroRNA 34b	RNA Gene	6.53	DISEASES inferred ¹⁴ ¹⁴
18	MIR3074	MicroRNA 3074	RNA Gene	6.5	DISEASES inferred ¹⁴ ¹⁴
19	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	6.33	DISEASES inferred ¹⁴
20	MIR34C	MicroRNA 34c	RNA Gene	6.31	DISEASES inferred ¹⁴ ¹⁴
21	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	6.28	DISEASES inferred ¹⁴ ¹⁴
22	CD274	CD274 Molecule	Protein Coding	6.27	DISEASES inferred ¹⁴
23	CD8A	CD8a Molecule	Protein Coding	6.27	DISEASES inferred ¹⁴
24	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	6.26	DISEASES inferred ¹⁴
25	FBXW7	F-Box And WD Repeat Domain Containing 7	Protein Coding	6.25	DISEASES inferred ¹⁴
26	MSH6	MutS Homolog 6	Protein Coding	6.24	DISEASES inferred ¹⁴
27	MLH1	MutL Homolog 1	Protein Coding	6.18	DISEASES inferred ¹⁴
28	PMS2	PMS1 Homolog 2, Mismatch Repair System Component	Protein Coding	6.17	DISEASES inferred ¹⁴
29	CTNNB1	Catenin Beta 1	Protein Coding	6.16	DISEASES inferred ¹⁴
30	DGCR5	DiGeorge Syndrome Critical Region Gene 5	RNA Gene	6.15	DISEASES inferred ¹⁴ ¹⁴
31	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	6.13	DISEASES inferred ¹⁴
32	MSH2	MutS Homolog 2	Protein Coding	6.11	DISEASES inferred ¹⁴
33	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	6.11	DISEASES inferred ¹⁴
34	MIR216B	MicroRNA 216b	RNA Gene	6.1	DISEASES inferred ¹⁴ ¹⁴
35	ESR1	Estrogen Receptor 1	Protein Coding	6.1	DISEASES inferred ¹⁴
36	EGFR	Epidermal Growth Factor Receptor	Protein Coding	6.08	DISEASES inferred ¹⁴
37	MIR452	MicroRNA 452	RNA Gene	6.02	DISEASES inferred ¹⁴ ¹⁴
38	CCNE1	Cyclin E1	Protein Coding	5.94	DISEASES inferred ¹⁴
39	PIK3R1	Phosphoinositide-3-Kinase Regulatory Subunit 1	Protein Coding	5.94	DISEASES inferred ¹⁴
40	MIR19A	MicroRNA 19a	RNA Gene	5.93	DISEASES inferred ¹⁴ ¹⁴
41	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	5.91	DISEASES inferred ¹⁴
42	PGR	Progesterone Receptor	Protein Coding	5.82	DISEASES inferred ¹⁴
43	CTLA4	Cytotoxic T-Lymphocyte Associated Protein 4	Protein Coding	5.82	DISEASES inferred ¹⁴
44	CD4	CD4 Molecule	Protein Coding	5.81	DISEASES inferred ¹⁴
45	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	5.79	DISEASES inferred ¹⁴
46	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	5.76	DISEASES inferred ¹⁴
47	PDCD1	Programmed Cell Death 1	Protein Coding	5.75	DISEASES inferred ¹⁴
48	AURKA	Aurora Kinase A	Protein Coding	5.71	DISEASES inferred ¹⁴
49	GAPDH	Glyceraldehyde-3-Phosphate Dehydrogenase	Protein Coding	5.65	DISEASES inferred ¹⁴
50	LAG3	Lymphocyte Activating 3	Protein Coding	5.61	DISEASES inferred ¹⁴

Sources

Variations for Uterine Corpus Cancer

Copy number variations for Uterine Corpus Cancer from CNVD:

⁶

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	162862	22	22706138	22714284	Decreasing copy number	GSTT1	Corpus uteri cancer

Sources

Expression for Uterine Corpus Cancer

Search GEO for disease gene expression data for Uterine Corpus Cancer.

Sources

Pathways for Uterine Corpus Cancer

Pathways related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

(show all 26)

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.58	TP53 PTEN PIK3CA HRAS ERBB2
2	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.39	TP53 PIK3CA HRAS ERBB2
3	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.33	TP53 PIK3CA HRAS ERBB2
4	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.23	ERBB2 HRAS PIK3CA PTEN TP53
5	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.2	ERBB2 HRAS PIK3CA PTEN TP53
6	Focal adhesion ⁷⁴	12.17	PTEN PIK3CA HRAS ERBB2
7	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.12	TP53 PTEN PIK3CA HRAS
8	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.04	TP53 PTEN PIK3CA HRAS ERBB2
9	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.02	TP53 PTEN PIK3CA HRAS
10	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	11.98	ERBB2 HRAS PIK3CA PTEN
11	Senescence and autophagy in cancer ⁷⁴	11.83	TP53 PTEN HRAS
12	Small cell lung cancer ⁷⁴	11.78	TP53 PTEN PIK3CA
13	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²²	11.78	PTEN PIK3CA HRAS ERBB2
14	Thyroid hormones production and peripheral downstream signaling effects ⁷⁴	11.71	TP53 PIK3CA HRAS
15	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.68	TP53 PIK3CA HRAS
16	16p11.2 proximal deletion syndrome ⁷⁴	11.64	TP53 PTEN PPP2R1A
17	p53 transcriptional gene network ⁷⁴	11.6	PTEN MIR34C MIR34B MIR200C
18	BCR signaling pathway ⁶¹	11.57	HRAS PIK3CA PTEN
19	DNA damage response (only ATM dependent) ⁷⁴	11.56	TP53 PTEN PIK3CA HRAS ERBB2
20	Copper homeostasis ⁷⁴ Show member pathways Copper metabolism ⁷⁴ Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) ⁶⁶	11.51	TP53 PTEN PIK3CA
21	miRNAs involved in DNA damage response ⁷⁴	11.38	TP53 MIR34C MIR34B MIR3074
22	Bladder cancer ⁷⁴	11.3	TP53 HRAS ERBB2
23	a6b1 and a6b4 Integrin signaling ⁶¹	11.24	PIK3CA HRAS ERBB2
24	Head and neck squamous cell carcinoma ⁷⁴	11.22	TP53 PTEN PIK3CA HRAS ERBB2
25	PI3K-AKT-mTOR signaling pathway and therapeutic opportunities ⁷⁴	11.13	PTEN PIK3CA HRAS
26	Pathways affected in adenoid cystic carcinoma ⁷⁴	10.89	TP53 PTEN PIK3CA HRAS ERBB2 ARID1A

Sources

GO Terms for Uterine Corpus Cancer

Biological processes related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	phosphatidylinositol 3-kinase signaling	GO:0014065	9.73	PTEN PIK3CA ERBB2
2	miRNA-mediated gene silencing	GO:0035195	9.73	MIR34C MIR34B MIR3074 MIR200C MIR139 MIR10B
3	positive regulation of connective tissue replacement	GO:1905205	9.32	MIR34C MIR34B
4	positive regulation of cardiac muscle hypertrophy in response to stress	GO:1903244	9.16	MIR34C MIR34B
5	negative regulation of protein kinase B signaling	GO:0051898	9.02	PTEN MIR34C MIR34B MIR200C

Molecular functions related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA base-pairing translational repressor activity	GO:1903231	9.43	MIR34C MIR34B MIR200C MIR139 MIR10B MIR101-1
2	mRNA 3'-UTR binding	GO:0003730	9.23	TP53 MIR34C MIR34B MIR200C MIR139 MIR10B